{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:08:00Z","timestamp":1776164880763,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The U.S. Food and Drug Administration released in January 2026 a draft guidance on the use of Bayesian methodology in clinical trials of drugs and biological products, representing a significant evolution in its regulatory approach to evaluating evidence supporting marketing authorization. The guidance reflects a growing consensus in regulatory science that traditional frequentist clinical efficacy trials, particularly equivalence and non-inferiority designs, are often poorly aligned with the scientific questions regulators must answer, mainly when substantial prior knowledge exists. This review examines the scientific literature questioning the value of routine clinical efficacy testing, with particular emphasis on biosimilars, and explains how Bayesian inference provides a coherent framework for integrating analytical, pharmacokinetic, clinical, and real-world evidence. The article analyzes the structure and reasoning of the FDA's new guidance, showing how it formalizes a justification-first approach to clinical testing and has potential implications beyond biosimilars, particularly where prior evidence is strong. The review addresses both the advantages and limitations of Bayesian regulatory applications, including potential failure modes and necessary safeguards. Finally, the broader implications of Bayesian regulatory decision-making for drug development efficiency, ethical standards, and global regulatory harmonization are discussed.<\/jats:p>","DOI":"10.3389\/fmed.2026.1790396","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:49:42Z","timestamp":1776160182000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The FDA's adoption of Bayesian methodology: transforming clinical trial justification from biosimilars to broader drug development"],"prefix":"10.3389","volume":"13","author":[{"given":"Sarfaraz K.","family":"Niazi","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences, University of Illinois","place":["Chicago, IL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","article-title":"Bayesian Approaches to Clinical Trials and Health-Care Evaluation","volume-title":"ISBN","author":"Spiegelhalter","year":"2004"},{"key":"B2","unstructured":"Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations\n          \n          \n          2020"},{"key":"B3","article-title":"Bayesian Data Analysis (3rd edn.). Boca Raton, FL: CRC Press","volume-title":"ISBN","author":"Gelman","year":"2013"},{"key":"B4","unstructured":"Guideline on similar biological medicinal products (CHMP\/437\/04 Rev\n          \n          \n            \n              European\n              Medicines Agency\n            \n          \n          \n          2014"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1517\/14712598.2012.711308","article-title":"The safety of switching between therapeutic proteins","volume":"12","author":"Ebbers","year":"2012","journal-title":"Expert Opinion Biol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","article-title":"Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes","volume":"78","author":"Cohen","year":"2018","journal-title":"Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.2147\/DDDT.S378813","article-title":"Scientific rationale for waiving clinical efficacy testing of biosimilars","volume":"16","author":"Niazi","year":"2022","journal-title":"Drug Design, Development Therapy."},{"key":"B8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ph18060779","article-title":"Scientific justification and policy recommendations to the US food and drug administration for waiving comparative efficacy studies","volume":"18","author":"Niazi","year":"2025","journal-title":"Pharmaceuticals."},{"key":"B9","unstructured":"Guidance for the use of Bayesian statistics in medical device clinical trials\n          \n          \n          2010"},{"key":"B10","unstructured":"Adaptive designs for clinical trials of drugs and biologics: guidance for industry\n          \n          \n          2019"},{"key":"B11","article-title":"Clinical trials: a methodological perspective (3rd edn","author":"Piantadosi","year":"2017"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1745-6215-8-31","article-title":"Responder analyses and the assessment of a clinically relevant treatment effect","volume":"8","author":"Snapinn","year":"2007","journal-title":"Trials."},{"key":"B13","article-title":"Bayesian Adaptive Methods for Clinical Trials","volume-title":"ISBN","author":"Berry","year":"2011"},{"key":"B14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"New Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1002\/sim.6225","article-title":"Bayesian methods for the design and interpretation of clinical trials in very rare diseases","volume":"33","author":"Hampson","year":"2014","journal-title":"Statistics Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: Context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Statistic."},{"key":"B17","unstructured":"Use of Bayesian methodology in clinical trials of drug and biological products: draft guidance for industry (Docket No\n          \n          \n          2026"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1541-0420.2011.01564.x","article-title":"Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials","volume":"67","author":"Hobbs","year":"2011","journal-title":"Biometrics."},{"key":"B19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1214\/06-BA129","article-title":"Checking for prior-data conflict","volume":"1","author":"Evans","year":"2006","journal-title":"Bayesian analysis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","article-title":"The combination of randomized and historical controls in clinical trials","volume":"29","author":"Pocock","year":"1976","journal-title":"J Chronic Dis."},{"key":"B21","article-title":"Bayesian inference for partially identified models: exploring the limits of limited data","volume-title":"ISBN","author":"Gustafson","year":"2015"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/0470033312","article-title":"Uncertain judgements: eliciting experts' probabilities. Hoben, NJ: John Wiley and Sons","author":"O'Hagan","year":"2006","journal-title":"ISBN"},{"key":"B23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/biologics2030014","article-title":"Biosimilars: harmonizing the approval guidelines","volume":"2","author":"Niazi","year":"2022","journal-title":"Biologics."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcpt.13743","article-title":"No two classes of biosimilars: urgent advice to the US Congress and the FDA","volume":"47","author":"Niazi","year":"2022","journal-title":"J Clinic Pharm Therap."},{"key":"B25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14712598.2022.2020241","article-title":"Biosimilars: a futuristic fast-to-market advice to developers","volume":"22","author":"Niazi","year":"2022","journal-title":"Expert Opinion Biol Therapy."},{"key":"B26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/1467-9884.00068","article-title":"The choice of sample size","volume":"46","author":"Lindley","year":"1997","journal-title":"J Royal Statist Society: series D (statist)."},{"key":"B27","first-page":"197","article-title":"Bayesian analysis of clinical trials with very small samples","volume":"60","author":"Christen","year":"2004","journal-title":"Biometrics."},{"key":"B28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1214\/ss\/1177012386","article-title":"Comment: a Bayesian perspective","volume":"4","author":"Kass","year":"1989","journal-title":"Statistical Sci."},{"key":"B29","first-page":"2979","article-title":"Trying to be precise about vagueness","volume":"27","author":"Senn","year":"2008","journal-title":"Statist Med."},{"key":"B30","unstructured":"4th edn.\n          International Ethical Guidelines for Health-Related Research Involving Humans"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1001\/jama.283.20.2701","article-title":"What makes clinical research ethical?","volume":"283","author":"Emanuel","year":"2000","journal-title":"JAMA."},{"key":"B32","unstructured":"ICH E9(R1): addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials\n          \n          \n            \n              International\n              Council for Harmonisation\n            \n          \n          \n          2019"},{"key":"B33","unstructured":"Reflection paper on the use of extrapolation in the development of medicines for paediatrics (EMA\/189724\/2018) (2019)\n          \n          \n            \n              European\n              Medicines Agency"},{"key":"B34","unstructured":"ICH E8(R1): general considerations for clinical studies\n          \n          \n            \n              International\n              Council for Harmonisation\n            \n          \n          \n          2016"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014What is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"New Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","article-title":"The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review","volume":"108","author":"Barbier","year":"2020","journal-title":"Clinic Pharmacol Therapeutics."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1790396\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:49:48Z","timestamp":1776160188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1790396\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1790396"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1790396","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1790396"}}